Mouse models of α-synucleinopathy and Lewy pathology: α-synuclein expression in transgenic mice

Advances in Experimental Medicine and Biology

Volumn 487, Issue , 2001, Pages 147-167

  Barbieri, S ^a   Hofele, K ^a   Wiederhold, K H ^a   Probst, A ^a   Mistl, C ^a   Danner, S ^a   Kauffmann, S ^a   Sommer, B ^a   Spooren, W ^a   Tolnay, M ^a   Bilbe, G ^a   Van der Putten, H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CONFERENCE PAPER; GENE MUTATION; LEWY BODY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0034982293     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1249-3_13     Document Type: Conference Paper

References (110)

1. Neuropathology of Parkinson's disease
2. Dementia with Lewy bodies. A distinct non AIzheimer dementia syndrome
3. Abnormal accumulation of NACP/α synuclein in neurodegenerative disorders
4. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
5. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
6. Extensive axonal Lewy neurites in Parkinson's disease: A novel pathological feature revealed by α-synuclein immunocytochemistry
7. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
8. α-Synuclein in Lewy bodies
9. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and Dementia with Lewy bodies
10. α-Synuclein is present in Lewy bodies in sporadic Parkinson's disease
11. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans
12. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein
13. A panel of epitope-specific antibodies detects protein domains distributed throughout human α-synuclein in Lewy bodies of Parkinson's disease
14. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease
15. Ubiquitin carboxyl-terminal hydrolase (PGP9.5) is selectively present in ubiquinated inclusion bodies characteristic of human degenerative disorders
16. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
17. Pathology and biology of the Lewy body
18. Mutation in the α-synuclein gene identified in families with Parkinson's disease
19. Ala30Pro mutation in the gene encoding α synuclein in Parkinson's disease
20. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease
21. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
22. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
23. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
24. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease
25. A Drosophila model of Parkinson's disease
26. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
27. Neuropathology in mice expressing human α-synuclein
28. Physiology and pathophysiology of α synuclein: Cell culture and transgenic animal models based on a Parkinson's disease associated protein
29. 5'upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice
30. Identification of cell type-specific promoter elements associated with the rat tyrosine hydroxylase gene using transgenic founder analysis
31. An endogenous serine protease inhibitor alters epileptic activity and hippocampal long-term potentiation
32. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
33. Neuron-specific transgene expression in brain of mouse bcl-XL but not human bcl-2 gene reduces lesion size following permanent MCAO
34. Overexpression of the neuronal growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice
35. Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein
36. Alzheimer's plaques and tangles: A controlled and enhanced silver staining method
37. Silver staining method for demonstrating Lewy bodies in Parkinson's disease and argyrophilic oligodendrocytes in multiple system atrophy
38. Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson's disease are detectable by an advanced silver-staining technique
39. α-synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining
40. Relationships between Lewy bodies and pale bodies in Parkinson's disease
41. The ubiquitin system
42. The ligation systems for ubiquitin and ubiquitin-like proteins
43. Ubiquitin-like proteins: New wines in new bottles
44. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease
45. Low frequency of alpha-synuclein mutations in familial Parkinson's disease
46. Alpha-synuclein gene and Parkinson's disease
47. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases
48. Proteasome inhibitors: Valuable new tools for cell biologists
49. Prospects for new restorative and neuroprotective treatements in Parkinson's disease
50. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
51. Membrane association and protein conformation of alpha-synuclein in intact neurons: Effect of Parkinson's disease-linked mutations
52. Alpha-synuclein in Lewy body disease and Alzheimer's disease
53. NACP, the precursor protein of non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation
54. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by α- and β synucleins
55. α-synuclein shares physical and functional homology with 14-3-3 proteins
56. α-synuclein binds to tau and stimulates the protein kinase A-catalysed tau phosphorylation of serine residues 262 and 356
57. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments
58. Synphilin-1 associates with α synuclein and promotes the formation of cytosolic inclusions
59. Synphilin-1 is present in Lewy bodies in Parkinson's disease
60. Axonal transport of synucleins is mediated by all rate components
61. Preassembly and transport of nerve terminals: A new concept of axonal transport
62. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
63. Expression pattern of synucleins (non-Aβ component of Alzheimer's disease amyloid precursor protein/α-synuclein) during murine brain development
64. Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system
65. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes
66. Synucleins are developmentally expressed, and α-synuclein regulates the size of presynaptic vesicular pool in primary hippocampal neurons
67. Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages
68. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein
69. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation
70. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
71. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
72. Degradation of alpha-synuclein by proteasome
73. The ubiquitin pathway in Parkinson's disease
74. Pattern of brain destruction in Parkinson's and Alzheimer's diseases
75. Parkinson's disease: Affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system
76. Paralysis agitans I Pathologische Anatomie
77. Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system
78. Ageing and Parkinson's disease: Substantia nigra regional selectivity
79. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease
80. The brain-stem lesions in parkinsonism
81. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease
82. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway
83. The audiospinal reaction in parkinsonian patients reflects functional changes in reticular nuclei
84. Amygdala pathology in Parkinson's disease
85. Nigral and extranigral pathology in Parkinson's disease
86. The greater lymbic system, the emotional motor system and the brain
87. Clinical and neuropathological correlates of dementia with Lewy bodies
88. Polyglutamine expansions: Proteolysis, chaperones, and the dangers of promiscuity
89. Immunoelectron microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous components of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies
90. Accumulation of α synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy
91. Synthetic filaments assembled from C-terminally truncated α-synuclein
92. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
93. The neuroimminue hypothesis in Parkinson's disease
94. FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells
95. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
96. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain
97. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice
98. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
99. Glutathione peroxidase protects against peroxynitrite-mediated oxidations
100. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
101. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
102. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyrirdine)-induced dopaminergic neurotoxicity
103. Inhibition of neuronal nitric oxide synthase prevent MPTP-induced parkinsonism in baboons
104. S-methylthiocitrulline, a neural nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity
105. NOS knockouts and neuroprotection
106. Protein nitration in Parkinson's disease
107. Dityrosine cross-linking promotes formation of stable α-synuclein polymers: Implication of nitrative and oxidative stress in pathogenesis of neurodegenerative synucleinopathies
108. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
109. Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation
110. Tyrosine hydroxylase and Parkinson's disease